glp-1 receptor agonists brand names Agonist Companies and Competitive Landscape A Tale of Two Incretins
Description
doi: 10.1016/j.jacbts.2018.09.004 61 SavareseGBecherPMLundLHSeferovicPRosanoGMCCoatsAJS
The second group included individuals who started and continued either a GLP-1 receptor agonist or SGLT-2 inhibitor for the first time between January 1, 2013, and December 31, 2020
GH reports research grants from the Netherlands Organization for Scientific Research (vidi 016.156.445), CardioVascular Research Initiative, European Union and the Klinkerpad fonds, institutional research support from Aegerion, Amgen, AstraZeneca, Eli Lilly, Genzyme, Ionis, Kowa, Pfizer, Regeneron, Roche, Sanofi, and The Medicines Company
Ethics declarations Competing interests D.S.P
Lancet 384 , 13491357 (2014)
